Metabolomics (WG-M)
Membership
Name | Position | Country | Term | Time in Office |
E. Fux | Chair | DE | 1st | 2021 10 - 2023 12 |
A. Bendt | Member | SG | | |
D. Di Natale | Member | IT | | |
D. Friedecky | Member | CZ | | |
J. Ivanisevic | Member | CH | | |
J. Otvos | Member | US | | |
Terms of Reference
- Assess Metabolomics approaches and Identify barriers/ challenges for clinical applications .
- Recommend solutions to facilitate the translation from academic laboratories to clinical laboratories
Objectives
- To evaluate and monitor emerging trends of Research in the field of Metabolomics.
- To provide an overview on metabolite discovery strategies by combining metabolomics with orthogonal experimental and computational biology approaches.
- To assess the applications of Metabolomics in clinical diagnosis and prognosis.
- To develop periodic updates of the applications on Metabolomics technologies and methods in clinical diagnosis.
- To assess the accessibility and the barriers to routine implementation of Metabolomics in clinical laboratories.
- To develop a resource that will inform the IFCC community on developments in the applications of Metabolomics in Clinical Diagnosis /Prognosis as well as methods/technologies in the IVD Market.
List of Corresponding Members, nominated by National Societies
Name | Full or Affiliate Member Societies |
Marie Lenski | Société Française de Biologie Clinique (SFBC) |
Working Group Chair contacts:
Dr. Elie Fux
Group Head Analytics - Early Development
Roche Diagnostics Penzberg - Germany
E-mail: elie.fux@roche.com